Your browser is no longer supported. Please, upgrade your browser.
Settings
ILMN Illumina, Inc. daily Stock Chart
ILMN [NASD]
Illumina, Inc.
IndexS&P 500 P/E65.38 EPS (ttm)4.67 Insider Own0.40% Shs Outstand147.00M Perf Week13.08%
Market Cap42.68B Forward P/E43.79 EPS next Y6.98 Insider Trans-14.99% Shs Float145.94M Perf Month-13.00%
Income693.00M PEG10.01 EPS next Q0.81 Inst Own94.40% Short Float2.76% Perf Quarter-15.69%
Sales3.35B P/S12.74 EPS this Y19.70% Inst Trans1.57% Short Ratio3.12 Perf Half Y10.58%
Book/sh31.04 P/B9.84 EPS next Y55.44% ROA9.60% Target Price303.73 Perf Year1.39%
Cash/sh23.39 P/C13.06 EPS next 5Y6.53% ROE15.20% 52W Range196.78 - 404.20 Perf YTD-7.92%
Dividend- P/FCF40.80 EPS past 5Y23.20% ROI15.80% 52W High-24.22% Beta0.95
Dividend %- Quick Ratio3.40 Sales past 5Y13.70% Gross Margin70.30% 52W Low55.66% ATR15.40
Employees7700 Current Ratio3.80 Sales Q/Q-24.50% Oper. Margin25.70% RSI (14)41.88 Volatility5.38% 4.92%
OptionableYes Debt/Eq0.25 EPS Q/Q-84.00% Profit Margin20.70% Rel Volume1.04 Prev Close305.46
ShortableYes LT Debt/Eq0.14 EarningsAug 06 AMC Payout0.00% Avg Volume1.29M Price306.30
Recom2.60 SMA20-5.28% SMA50-12.79% SMA200-5.74% Volume995,733 Change0.28%
Sep-29-20Downgrade Wolfe Research Outperform → Peer Perform
Sep-22-20Downgrade UBS Buy → Neutral $390 → $285
Sep-22-20Downgrade Stifel Buy → Hold $380 → $280
Sep-21-20Upgrade Guggenheim Neutral → Buy $345
Sep-21-20Downgrade JP Morgan Overweight → Neutral $390 → $280
Sep-09-20Initiated Morgan Stanley Equal-Weight $400
Aug-07-20Downgrade Piper Sandler Overweight → Neutral $356 → $340
Aug-07-20Downgrade Evercore ISI In-line → Underperform $310
Jul-07-20Downgrade Guggenheim Buy → Neutral
Apr-24-20Downgrade Citigroup Buy → Neutral $250 → $320
Apr-21-20Downgrade Robert W. Baird Outperform → Neutral $310
Jan-08-20Initiated Wells Fargo Underweight $300
Jan-07-20Initiated Citigroup Buy $385
Jan-02-20Downgrade Evercore ISI Outperform → In-line $330 → $340
Nov-15-19Initiated Stifel Buy
Oct-25-19Initiated Guggenheim Buy $350
Jul-30-19Downgrade Canaccord Genuity Buy → Hold $330 → $300
Jul-12-19Downgrade BofA/Merrill Buy → Underperform
May-30-19Initiated Wolfe Research Outperform
Jan-03-19Upgrade UBS Neutral → Buy
Sep-28-20 07:00AM  
Sep-24-20 02:47PM  
11:40AM  
Sep-23-20 04:05PM  
Sep-22-20 02:23PM  
09:57AM  
09:45AM  
09:27AM  
08:26AM  
06:14AM  
05:45AM  
02:16AM  
Sep-21-20 04:27PM  
04:09PM  
02:13PM  
02:04PM  
12:15PM  
11:37AM  
10:32AM  
09:59AM  
09:18AM  
09:15AM  
08:34AM  
07:29AM  
07:07AM  
07:00AM  
Sep-17-20 10:28AM  
09:56AM  
09:50AM  
08:00AM  
03:33AM  
Sep-16-20 05:51PM  
02:20PM  
01:24PM  
11:55AM  
07:11AM  
Sep-15-20 05:00AM  
Sep-14-20 10:10PM  
Sep-13-20 06:52AM  
Sep-10-20 08:00PM  
08:00PM  
Sep-09-20 05:44PM  
03:54PM  
09:44AM  
Sep-05-20 11:32AM  
Sep-03-20 08:11AM  
06:11AM  
04:00AM  
Sep-02-20 12:47PM  
Aug-25-20 08:30AM  
Aug-24-20 11:40AM  
Aug-18-20 11:15AM  
Aug-12-20 12:51PM  
Aug-11-20 09:00AM  
Aug-10-20 09:31AM  
Aug-07-20 01:24PM  
11:40AM  
10:29AM  
08:55AM  
07:41AM  
Aug-06-20 05:30PM  
05:25PM  
05:10PM  
04:36PM  
04:05PM  
Aug-04-20 06:40AM  
Aug-03-20 01:49AM  
Jul-30-20 12:33PM  
09:16AM  
Jul-28-20 09:48AM  
Jul-27-20 01:01PM  
Jul-25-20 07:30AM  
Jul-22-20 11:23AM  
Jul-21-20 06:08AM  
Jul-17-20 11:40AM  
Jul-16-20 04:05PM  
Jul-12-20 06:12AM  
Jul-08-20 09:01AM  
Jun-30-20 11:18AM  
Jun-29-20 11:40AM  
09:44AM  
Jun-25-20 07:49AM  
Jun-23-20 07:19AM  
02:01AM  
Jun-19-20 12:01PM  
Jun-18-20 11:06AM  
Jun-17-20 07:01PM  
Jun-16-20 04:05PM  
Jun-12-20 11:40AM  
Jun-10-20 11:49AM  
09:53AM  
07:30AM  
Jun-09-20 10:36PM  
10:23AM  
10:05AM  
Jun-08-20 10:22AM  
Jun-05-20 09:47AM  
09:21AM  
Jun-03-20 03:47AM  
Jun-01-20 11:00AM  
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FLATLEY JAY TDirectorSep 15Sale355.224,0001,420,880210,933Sep 17 04:59 PM
TOUSI SUSAN HSVP Product DevelopmentSep 09Sale350.0020070,00045,268Sep 10 04:49 PM
TOUSI SUSAN HSVP Product DevelopmentSep 08Sale336.0010033,60045,468Sep 10 04:49 PM
Van Oene MarkSVP Chief Commercial OfficerSep 01Sale355.13625221,95317,648Sep 02 07:52 PM
deSouza Francis APresident and CEOSep 01Sale352.323,0001,056,96471,840Sep 02 07:49 PM
Dadswell CharlesSVP & General CounselSep 01Sale355.351,687599,4756,278Sep 02 07:45 PM
FLATLEY JAY TDirectorSep 01Sale355.354,0001,421,400214,933Sep 02 07:35 PM
RAGUSA ROBERT PSVP, Global Quality & OpsAug 31Sale355.185,0001,775,9078,103Sep 02 07:29 PM
FLATLEY JAY TDirectorAug 18Sale354.034,0001,416,120218,933Aug 20 05:14 PM
MCGINNIS KAREN KVP, Chief Accounting OfficerAug 10Sale357.011,856662,6112,350Aug 12 04:32 PM
TOUSI SUSAN HSVP Product DevelopmentAug 05Sale399.03800319,22045,568Aug 06 04:21 PM
Hoyt Aimee LSVP, Chief People OfficerAug 04Sale397.732911,5343,498Aug 05 05:57 PM
FLATLEY JAY TDirectorAug 04Sale397.734,0001,590,920222,933Aug 05 05:54 PM
Van Oene MarkSVP Chief Commercial OfficerAug 03Sale385.43625240,89418,255Aug 05 05:50 PM
Dadswell CharlesSVP & General CounselAug 03Sale385.1912146,6087,913Aug 05 05:41 PM
deSouza Francis APresident and CEOAug 03Sale389.853,0001,169,54374,822Aug 05 04:57 PM
FLATLEY JAY TDirectorJul 21Sale399.004,0001,596,000226,933Jul 22 04:46 PM
TOUSI SUSAN HSVP Product DevelopmentJul 20Sale400.00500200,00046,354Jul 22 04:49 PM
FLATLEY JAY TDirectorJul 07Sale370.224,0001,480,880230,933Jul 08 04:52 PM
TOUSI SUSAN HSVP Product DevelopmentJul 06Sale375.00300112,50046,854Jul 08 04:40 PM
Van Oene MarkSVP Chief Commercial OfficerJul 01Sale369.40625230,87418,880Jul 06 04:25 PM
deSouza Francis APresident and CEOJul 01Sale366.653,0001,099,96078,158Jul 06 04:13 PM
Dadswell CharlesSVP & General CounselJul 01Sale369.2612144,6808,034Jul 06 04:07 PM
FLATLEY JAY TDirectorJun 16Sale354.934,0001,419,720234,933Jun 17 04:18 PM
RAGUSA ROBERT PSVP, Global Quality & OpsJun 15Sale340.765,0001,703,80913,056Jun 17 04:15 PM
Hoyt Aimee LSVP, Chief People OfficerJun 08Sale350.9419167,0303,498Jun 10 05:09 PM
FLATLEY JAY TDirectorJun 02Sale364.404,0001,457,600238,933Jun 03 04:37 PM
deSouza Francis APresident and CEOJun 01Sale362.783,0001,088,32981,158Jun 03 04:34 PM
Van Oene MarkSVP Chief Commercial OfficerJun 01Sale361.54625225,96319,505Jun 03 04:27 PM
Dadswell CharlesSVP & General CounselJun 01Sale362.601,686611,3448,155Jun 03 04:25 PM
TOUSI SUSAN HSVP Product DevelopmentMay 28Sale375.00600225,00047,154Jun 01 04:34 PM
SAMAD SAMSVP and CFOMay 26Sale360.001,356488,1603,879May 28 06:20 PM
TOUSI SUSAN HSVP Product DevelopmentMay 20Sale350.00300105,00047,754May 21 04:51 PM
FLATLEY JAY TDirectorMay 19Sale342.344,0001,369,360241,970May 20 06:48 PM
SAMAD SAMSVP and CFOMay 18Sale340.001,357461,3805,235May 20 06:50 PM
TOUSI SUSAN HSVP Product DevelopmentMay 12Sale325.00600195,00048,054May 13 06:08 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanMay 11Sale315.132,140674,36917,172May 13 06:04 PM
ARNOLD FRANCESDirectorMay 11Sale309.111,503464,5929,954May 13 05:57 PM
FLATLEY JAY TDirectorMay 05Sale310.373,000931,110245,970May 07 05:57 PM
Van Oene MarkSVP Chief Commercial OfficerMay 01Sale316.83625198,01620,130May 05 07:01 PM
deSouza Francis APresident and CEOMay 01Sale308.613,000925,81984,158May 05 06:35 PM
Dadswell CharlesSVP & General CounselMay 01Sale317.1612138,3769,841May 05 06:22 PM
FLATLEY JAY TDirectorApr 21Sale310.773,000932,310248,970Apr 22 04:52 PM
SAMAD SAMSVP and CFOApr 20Sale320.021,356433,9476,592Apr 22 04:54 PM
SAMAD SAMSVP and CFOApr 16Sale300.001,697509,1007,948Apr 20 05:41 PM
Febbo Phillip G.SVP Chief Medical OfficerApr 16Sale300.0017351,9002,490Apr 20 05:39 PM
Van Oene MarkSVP Chief Commercial OfficerApr 16Sale300.221,250375,27520,755Apr 20 05:37 PM
SAMAD SAMSVP and CFOApr 14Sale292.5424972,8429,645Apr 16 04:25 PM
FLATLEY JAY TDirectorApr 07Sale284.632,000569,260251,970Apr 08 05:37 PM
deSouza Francis APresident and CEOApr 06Sale275.003,000825,00087,158Apr 07 04:26 PM
Dadswell CharlesSVP & General CounselApr 01Sale265.9212132,1769,962Apr 03 04:38 PM
Hoyt Aimee LSVP, Chief People OfficerMar 05Sale273.95417114,2373,689Mar 09 05:14 PM
FLATLEY JAY TDirectorMar 03Sale277.402,000554,800256,970Mar 04 04:31 PM
deSouza Francis APresident and CEOMar 02Sale275.003,000825,00090,158Mar 04 04:36 PM
Dadswell CharlesSVP & General CounselMar 02Sale268.021,686451,88210,083Mar 04 04:33 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanFeb 18Sale298.871,800537,95919,312Feb 20 05:04 PM
FLATLEY JAY TDirectorFeb 18Sale299.003,000897,000255,970Apr 08 05:37 PM
MCGINNIS KAREN KVP, Chief Accounting OfficerFeb 11Option Exercise0.001,00104,742Feb 13 08:15 PM
Van Oene MarkSVP Chief Commercial OfficerFeb 11Option Exercise0.0011,641030,166Feb 13 08:12 PM
TOUSI SUSAN HSVP Product DevelopmentFeb 11Option Exercise0.009,969055,574Feb 13 08:10 PM
SAMAD SAMSVP and CFOFeb 11Option Exercise0.006,626014,407Feb 13 08:09 PM
Ronaghi MostafaSVP & CTOFeb 11Option Exercise0.0011,728094,732Feb 13 08:08 PM
RAGUSA ROBERT PSVP, Global Quality & OpsFeb 11Option Exercise0.009,969024,976Feb 13 08:06 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanFeb 11Option Exercise0.0013,488030,643Feb 13 08:05 PM
deSouza Francis APresident and CEOFeb 11Option Exercise0.0035,1840118,817Feb 13 07:39 PM
Dadswell CharlesSVP & General CounselFeb 11Option Exercise0.007,624016,943Feb 13 07:36 PM
Van Oene MarkSVP Chief Commercial OfficerFeb 05Sale300.24625187,65010,623Feb 06 04:23 PM
SAMAD SAMSVP and CFOFeb 03Sale293.1023869,7583,011Feb 05 05:40 PM
RAGUSA ROBERT PSVP, Global Quality & OpsFeb 03Sale293.101,253367,2547,888Feb 05 05:37 PM
TOUSI SUSAN HSVP Product DevelopmentJan 06Sale325.0020065,00038,465Jan 08 04:10 PM
Van Oene MarkSVP Chief Commercial OfficerJan 02Sale330.99625206,86811,178Jan 06 04:12 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanDec 10Sale326.011,200391,2127,844Dec 12 05:13 PM
TOUSI SUSAN HSVP Product DevelopmentDec 06Sale325.001,000325,00038,665Dec 10 04:36 PM
Dadswell CharlesSVP & General CounselDec 02Sale320.33655209,8163,576Dec 04 07:25 PM
Van Oene MarkSVP Chief Commercial OfficerDec 02Sale320.15625200,09411,803Dec 04 07:19 PM
SAMAD SAMSVP and CFONov 29Sale320.00892285,4403,461Dec 03 08:35 PM
Febbo Phillip G.SVP Chief Medical OfficerNov 14Sale300.0015546,5001,506Nov 18 04:33 PM
RAGUSA ROBERT PSVP, Global Quality & OpsNov 01Sale297.281,674497,64710,192Nov 05 04:18 PM
Dadswell CharlesSVP & General CounselNov 01Sale297.2819357,3755,069Nov 05 04:55 PM
Van Oene MarkSVP Chief Commercial OfficerNov 01Sale300.10625187,56313,584Nov 05 04:50 PM
Ronaghi MostafaSVP & CTOOct 15Option Exercise69.344,000277,36080,585Oct 17 04:46 PM
Ronaghi MostafaSVP & CTOOct 15Sale310.934,0001,243,71176,585Oct 17 04:46 PM
Van Oene MarkSVP Chief Commercial OfficerOct 01Sale304.84625190,52514,209Oct 03 04:26 PM
Dadswell CharlesSVP & General CounselOct 01Sale304.2212437,7235,262Oct 03 04:24 PM